Harmony Biosciences Holdings logo

Harmony Biosciences HoldingsNASDAQ: HRMY

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

19 August 2020

Next earnings report:

21 February 2025

Last dividends:

N/A

Next dividends:

N/A
$1.89 B
-47%vs. 3y high
80%vs. sector
-92%vs. 3y high
25%vs. sector
-81%vs. 3y high
71%vs. sector
-71%vs. 3y high
45%vs. sector

Price

after hours | Fri, 01 Nov 2024 21:59:02 GMT
$33.08+$0.87(+2.70%)

Dividend

No data over the past 3 years
$186.04 M$198.13 M
$186.04 M$46.09 M

Analysts recommendations

Institutional Ownership

HRMY Latest News

Levi & Korsinsky Reminds Shareholders of an Investigation into Harmony Biosciences Holdings, Inc. (HRMY) Regarding Potential Securities Fraud Allegations
accesswire.com04 November 2024 Sentiment: -

NEW YORK, NY / ACCESSWIRE / November 4, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (NASDAQ:HRMY) concerning possible violations of federal securities laws. On March 28, 2023, Scorpion Capital published a report detailing a string of concerns with Harmony's narcolepsy drug, Wakix (pitolisant).

Are Investors Undervaluing Harmony Biosciences (HRMY) Right Now?
zacks.com01 November 2024 Sentiment: POSITIVE

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Harmony Biosciences Holdings, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - HRMY
accesswire.com01 November 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / November 1, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (NASDAQ:HRMY) concerning possible violations of federal securities laws. On March 28, 2023, Scorpion Capital published a report detailing a string of concerns with Harmony's narcolepsy drug, Wakix (pitolisant).

Harmony Biosciences Holdings, Inc. Announces Pricing of Public Offering of Common Stock by Selling Shareholders
prnewswire.com30 October 2024 Sentiment: POSITIVE

PLYMOUTH MEETING, Pa. , Oct. 30, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) (the "Company") today announced the pricing of the previously announced underwritten public offering of an aggregate of 8,000,000 shares of the Company's common stock, par value $0.00001 per share ("Common Stock"), by Marshman Fund Trust II and Valor IV Pharma Holdings, LLC (together, the "Selling Shareholders") at a public offering price of $31.00 per share.

HRMY ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Harmony Biosciences Holdings, Inc. Shareholders Who Lost Money
accesswire.com30 October 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / October 30, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (NASDAQ:HRMY) concerning possible violations of federal securities laws. On March 28, 2023, Scorpion Capital published a report detailing a string of concerns with Harmony's narcolepsy drug, Wakix (pitolisant).

Harmony Biosciences Holdings, Inc. Announces Commencement of Proposed Public Offering of Common Stock by Selling Shareholders
prnewswire.com29 October 2024 Sentiment: NEUTRAL

PLYMOUTH MEETING, Pa. , Oct. 29, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) (the "Company") today announced the commencement of an underwritten public offering of up to 8,000,000 shares of the Company's common stock, par value $0.00001 per share ("Common Stock"), by Marshman Fund Trust II and Valor IV Pharma Holdings, LLC (together, the "Selling Shareholders").

Harmony Biosciences Holdings, Inc. (HRMY) Q3 2024 Earnings Call Transcript
seekingalpha.com29 October 2024 Sentiment: NEUTRAL

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY ) Q3 2024 Earnings Conference Call October 29, 2024 8:30 AM ET Company Participants Brennan Doyle - Head of Investor Relations Jeffrey Dayno - President & Chief Executive Officer Jeffrey Dierks - Chief Commercial Officer Kumar Budur - Chief Medical Officer & Scientific Officer Sandip Kapadia - Chief Financial Officer & Chief Administrative Officer Conference Call Participants Graig Suvannavejh - Mizuho Ami Fadia - Needham Charles Duncan - Cantor Fitzgerald David Amsellem - Piper Sandler Danielle Brill - Raymond James Ash Verma - UBS Corinne Johnson - Goldman Sachs Jason Gerberry - Bank of America Francois Brisebois - Oppenheimer Operator Good morning. My name is Todd, and I will be your conference operator today.

Harmony Biosciences Holdings, Inc. (HRMY) Earnings Expected to Grow: Should You Buy?
zacks.com22 October 2024 Sentiment: POSITIVE

Harmony Biosciences (HRMY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

HARMONY BIOSCIENCES TO REPORT THIRD QUARTER 2024 FINANCIAL RESULTS ON OCTOBER 29, 2024
prnewswire.com16 October 2024 Sentiment: NEUTRAL

PLYMOUTH MEETING, Pa. , Oct. 16, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report third quarter 2024 financial results on Tuesday, October 29, 2024, before the open of the U.S. financial markets.

Lost Money on Harmony Biosciences Holdings, Inc. (HRMY)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky
accesswire.com11 October 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / October 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (NASDAQ:HRMY) concerning possible violations of federal securities laws. On March 28, 2023, Scorpion Capital published a report detailing a string of concerns with Harmony's narcolepsy drug, Wakix (pitolisant).

What type of business is Harmony Biosciences Holdings?

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

What sector is Harmony Biosciences Holdings in?

Harmony Biosciences Holdings is in the Healthcare sector

What industry is Harmony Biosciences Holdings in?

Harmony Biosciences Holdings is in the Biotechnology industry

What country is Harmony Biosciences Holdings from?

Harmony Biosciences Holdings is headquartered in United States

When did Harmony Biosciences Holdings go public?

Harmony Biosciences Holdings initial public offering (IPO) was on 19 August 2020

What is Harmony Biosciences Holdings website?

https://www.harmonybiosciences.com

Is Harmony Biosciences Holdings in the S&P 500?

No, Harmony Biosciences Holdings is not included in the S&P 500 index

Is Harmony Biosciences Holdings in the NASDAQ 100?

No, Harmony Biosciences Holdings is not included in the NASDAQ 100 index

Is Harmony Biosciences Holdings in the Dow Jones?

No, Harmony Biosciences Holdings is not included in the Dow Jones index

When was Harmony Biosciences Holdings the previous earnings report?

No data

When does Harmony Biosciences Holdings earnings report?

The next expected earnings date for Harmony Biosciences Holdings is 21 February 2025